Karius
26 articles about Karius
-
Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer
10/10/2023
A pivotal multi-center study published in Clinical Infectious Diseases demonstrates the effectiveness of the Karius Test®, a blood test based on metagenomics next generation sequencing of microbial cell-free DNA, by increasing the identification of pathogens causing pneumonia in immunocompromised patients by 40% (20/52) when combined with usual care diagnostic testing1.
-
Karius Inc. Adds Dr. Norman Sharpless, Former National Cancer Institute Head, and Elizabeth O'Farrell, Eli Lilly Veteran, to its Board of Directors
8/10/2023
Karius ® , Inc. a world leader in liquid biopsy for infectious diseases, is announcing the appointment of two healthcare veterans to its Board of Directors: Norman (Ned) Sharpless, M.D. and Elizabeth (Liz) O'Farrell.
-
Karius Test®, a Liquid Biopsy for Infectious Diseases, Incorporated into Diagnostics Recommendation in the 2023 Duke-ISCVID Criteria for Infective Endocarditis
8/2/2023
Karius®, Inc. a world leader in liquid biopsy for infectious diseases, has announced the inaugural inclusion of the Karius Test® in the 2023 Duke-ISCVID Criteria for Infective Endocarditis by the International Society of Cardiovascular Infectious Diseases.
-
Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants
4/11/2023
Karius® and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans.
-
Karius Prepares for Further Growth with New Chief Financial Officer, Chief Legal Officer Appointments
12/9/2021
Karius, the world leader in liquid biopsy for infectious diseases, announced the addition of two key executives to best position the company for continued growth.
-
Karius receives New York State permit for its liquid biopsy test to detect infectious diseases
8/17/2021
Karius has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.
-
Karius Strengthens Leadership Team, Names Former CDC Exec as Chief Medical Officer
5/27/2021
Leading authority on infectious disease, Dr. Bradley Perkins, to accelerate clinical evidence of the Karius Test™, a liquid biopsy for infectious disease
-
Karius Launches Multicenter Study to Evaluate the Diagnostic Value of the Karius Test for Pneumonia in Immunocompromised Patients
8/3/2020
Karius, the world leader in liquid biopsy for infectious diseases, announced today active enrollment in a multicenter, prospective study that will evaluate the diagnostic value of the Karius ® Test for pneumonia in immunocompromised adult patients including those with hematological cancers. The Karius Test is a non-invasive bloo
-
“This transformative round will allow Karius to help more patients faster, fuel the next wave of clinical studies and accelerate technology innovation,” said Karius’ chief executive officer Mickey Kertesz.
-
Karius Test® Demonstrates Ability To Detect Pathogens Standard Tests Can Miss In Pneumonia Cases
10/2/2019
Karius will present six studies at IDWeek™ 2019 highlighting the clinical utility of the Karius Test.
-
Study Validates Karius Test to Identify Life-Threatening Infections
2/11/2019
Karius, a life sciences company, announced today that the peer-reviewed journal Nature Microbiology published a study validating the Karius® Test for detecting pathogens and showing that the test identifies pathogens potentially faster than standard testing.
-
Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...
-
Karius and Dasa enter into a partnership to introduce the Karius Test into Brazil
10/29/2018
Karius, a life sciences company transforming infectious disease diagnostics with genomics, is forming a partnership with Dasa, the largest medical diagnostic company in Latin America, effective October 19, 2018.
-
Karius and Dasa enter into a partnership to introduce the Karius Test into Brazil
10/26/2018
The quantitative next-generation sequencing blood test for infectious diseases makes an international impact
-
Investor Enthusiasm About Liquid Biopsies Drives Guardant Health IPO to $1.59 Billion Valuation
10/5/2018
Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO). -
Karius Announces Winners of the 2018 Clinical Investigator Awards
10/1/2018
Karius today announced the winners for its 2018 Clinical Investigator Awards for Applied Infectious Disease Genomics.
-
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
-
Some diagnostics testing for infectious diseases can be quite invasive and uncomfortable for a patient. Now though, a new form of test is available that can mitigate the need for those invasive tests.
-
Journal of Diagnostic Microbiology and Infectious Disease Publishes New Clinical Study Data on Karius Test
7/17/2018
Study Confirms Liquid Biopsy for Infectious Diseases Accurately Detects Invasive Fungal Infections
-
Karius Announces Launch of Quantitative, Broad-Based Infectious Disease Diagnostic Test Using Microbial Cell-Free DNA Test Detects and Quantifies DNA from Bacteria, Viruses and Fungi in a Single Blood Sample
5/9/2018
Karius announced today that the new version of its proprietary Karius Test can now quantify the abundance of pathogens detected.